Aktis Oncology, Inc.

Aktis Oncology, Inc. - ROEverified

AKTS

Price:

$24.09

Market Cap:

$1.29B

Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast ca...[Read more]

Industry

Biotechnology

IPO Date

2026-01-09

Stock Exchange

NASDAQ

Ticker

AKTS

The ROE as of June 2026 (TTM) for Aktis Oncology, Inc. (AKTS) is -130.27%

According to Aktis Oncology, Inc.’s latest financial reports and current stock price. The company's current ROE is -130.27%. This represents a change of -2645.94% compared to the average of 5.12% of the last 4 quarters.

Aktis Oncology, Inc. (AKTS) Historical ROE (quarterly & annually)

How has AKTS ROE performed in the past?

The mean historical ROE of Aktis Oncology, Inc. over the last ten years is 62.20%. The current -130.27% ROE has changed -309.46% with respect to the historical average. Over the past ten years (40 quarters), AKTS's ROE was at its highest in in the December 2024 quarter at 13.73%. The ROE was at its lowest in in the March 2026 quarter at -3.62%.

Quarterly (TTM)
Annual

Average

62.20%

Median

55.97%

Minimum

43.61%

Maximum

93.23%

Aktis Oncology, Inc. (AKTS) ROE by Quarter and Year

Discovering the peaks and valleys of Aktis Oncology, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 0%

Maximum Annual ROE = 93.23%

Minimum Annual Increase = -33.66%

Minimum Annual ROE = 43.61%

Quarterly (TTM)
Annual
YearROEChange
202543.61%-12.94%
202450.09%-19.02%
202361.85%-33.66%

Aktis Oncology, Inc. (AKTS) Average ROE

How has AKTS ROE performed in the past?

The current ROE of Aktis Oncology, Inc. (AKTS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

51.85%

5-year avg

62.20%

10-year avg

62.20%

Aktis Oncology, Inc. (AKTS) ROE vs. Peers

How is AKTS’s ROE compared to its peers?

Aktis Oncology, Inc.’s ROE is

CompanyROEMarket cap

Build a custom stock screener for Aktis Oncology, Inc. (AKTS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aktis Oncology, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Aktis Oncology, Inc. (AKTS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Aktis Oncology, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the ROE?

How can you use the ROE?

What is Aktis Oncology, Inc.'s ROE?

How is the ROE calculated for Aktis Oncology, Inc. (AKTS)?

What is the highest ROE for Aktis Oncology, Inc. (AKTS)?

What is the 3-year average ROE for Aktis Oncology, Inc. (AKTS)?

What is the 5-year average ROE for Aktis Oncology, Inc. (AKTS)?

How does the current ROE for Aktis Oncology, Inc. (AKTS) compare to its historical average?